ATMP market seen nearly doubling by 2032

By AI, Created 5:35 AM UTC, May 22, 2026, /AGP/ – The global advanced therapy medicinal products market was valued at $16.60 billion in 2025 and is projected to reach nearly $39.55 billion by 2032, driven by gene, cell and tissue-based therapies. Growth is being fueled by rising chronic and rare disease demand, regulatory support and expanding clinical pipelines across North America, Europe and Asia-Pacific.

Why it matters: - Advanced therapy medicinal products are moving from niche science to a major treatment category for cancer, rare genetic disorders and other hard-to-treat conditions. - The market’s projected climb to nearly $39.55 billion by 2032 signals rising commercial momentum for personalized and regenerative medicine. - The shift could reshape how drugmakers, hospitals and researchers approach long-term and potentially curative care.

What happened: - The global advanced therapy medicinal products market was valued at $16.60 billion in 2025. - Market revenue is projected to grow at a 13.2% CAGR from 2026 to 2032. - The market is expected to reach nearly $39.55 billion by 2032. - The report covers gene therapies, cell therapies, tissue-engineered products and combined ATMPs. - Get a sample of the report.

The details: - Gene therapy holds a significant share because of rising approvals and progress in viral vector technologies. - Cell therapy is expected to grow the fastest as CAR-T and stem-cell therapies gain wider clinical acceptance. - Tissue-engineered products are gaining traction in orthopedic, dermatology and wound-healing uses. - Autologous therapies lead the therapy-type segment because they reduce immune rejection risk and improve compatibility. - Allogeneic therapies are gaining ground because they can be manufactured at scale and at lower cost. - Oncology remains the largest application area because of cell-based immunotherapies and gene-modified cancer treatments. - Rare genetic disorders, neurological disorders and cardiovascular diseases are expected to post strong growth during the forecast period. - Hospitals and specialty clinics account for the largest end-user share because they are the main sites for administering advanced therapies. - Academic and research institutes are helping drive innovation and clinical trial growth.

Between the lines: - The market’s growth is being driven by a mix of science and infrastructure. - Companies are advancing CRISPR-Cas9, viral vector optimization and induced pluripotent stem cell technologies to improve precision and expand treatable diseases. - Biotech and pharmaceutical companies are investing heavily in research, acquisitions and manufacturing capabilities to strengthen pipelines. - Regulatory support from the U.S. Food and Drug Administration and the European Medicines Agency is speeding development through fast-track approvals and orphan drug pathways. - The report points to rising clinical-trial activity in oncology, autoimmune disease, neurological disorders and rare conditions as a sign of longer-term demand. - CDMOs are becoming more important as drugmakers outsource complex manufacturing, including viral vectors, cell processing and GMP-compliant production. - North America leads the market because of strong biotech infrastructure, high healthcare spending, favorable reimbursement and more FDA approvals. - Europe is growing on supportive EMA regulation and personalized medicine adoption. - Asia-Pacific is expected to post the fastest CAGR, helped by biotechnology investment, better infrastructure and government support. - Geopolitical tensions involving America, Israel and Iran could disrupt supply chains, cold-chain logistics, raw materials and international clinical collaboration. - Those same pressures may also push countries to localize pharmaceutical manufacturing and build domestic biotech capacity.

What’s next: - Allogeneic “off-the-shelf” therapies are likely to attract more attention because they can improve scalability and lower costs. - Artificial intelligence, automation and advanced bioprocessing tools are expected to make manufacturing more efficient and less complex. - Emerging markets in Asia-Pacific, Latin America and the Middle East may draw more investment as healthcare systems expand. - Competitive activity is likely to remain intense as large drugmakers pursue acquisitions, partnerships, launches and trial expansion. - Key companies in the market include Novartis, Gilead Sciences, Bristol Myers Squibb, Bluebird Bio, Pfizer, Roche, Vericel, Sarepta Therapeutics, CRISPR Therapeutics, Vertex Pharmaceuticals, AstraZeneca and Bayer. - Access the full report.

The bottom line: - ATMPs are shifting from experimental promise to a high-growth global market, with oncology, gene editing and scalable manufacturing set to define the next phase.